U.S. Markets closed

Aerie Pharma's eye drug succeeds in mid-stage trial

June 25 (Reuters) - Drug developer Aerie Pharmaceuticals Inc said its once-daily eye treatment was shown to be superior to each of its two components in a mid-stage trial.

The drug, Roclatan, is a combination of Aerie's other eye drug Rhopressa and a glaucoma medication called latanoprost. The combination was being tested in glaucoma patients.

(Reporting By Amrutha Penumudi; Editing by Don Sebastian)